Literature DB >> 16123983

Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant.

Andrew L Gilman1, Amy Serrano, John Skelley, David Zwick.   

Abstract

We report the clinical course of a patient who developed a Rhizopus infection of his right lung and pleural cavity, 11 months after receiving a T-cell-depleted, haploidentical donor peripheral blood stem cell transplant. Thoracotomy was performed to remove the pulmonary lesion, but residual disease in the pleural cavity was noted. Treatment with amphotericin B was complicated by the development of severe renal dysfunction, necessitating alternative antifungal therapy. Treatment was initiated with the investigational triazole posaconazole. Despite concurrent treatment with corticosteroids for graft-versus-host disease (GVHD), the patient had a complete response and remains well 4 years later.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16123983     DOI: 10.1002/pbc.20572

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

1.  In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest.

Authors:  Marta Torres-Narbona; Jesús Guinea; José Martínez-Alarcón; Teresa Peláez; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

2.  Cavitary pulmonary zygomycosis caused by Rhizopus homothallicus.

Authors:  Arunaloke Chakrabarti; Rungmei S K Marak; M R Shivaprakash; Sunita Gupta; Rajiv Garg; V Sakhuja; Sanjay Singhal; Abhishek Baghela; Ajai Dixit; M K Garg; Arvind A Padhye
Journal:  J Clin Microbiol       Date:  2010-03-03       Impact factor: 5.948

3.  Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.

Authors:  Jun Feng; Xuefeng Sun
Journal:  Infection       Date:  2018-05-10       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.